NR4A1 and invasive breast carcinoma: Richter-Ehrenstein et al. suggested using adjuvant antihormonal therapy as the standard treatment approach in the hormone receptor-positive NECB.[29] The prognostic role of HER-2 in NECB is not clear, but it can be assumed that it is analogous to other invasive breast carcinomas, meaning that anti-HER2 therapy is recommended for HER2-positive NECB.